Navigation Links
World's Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc.

BUDAPEST, Hungary and LONDON and PRINCETON, New Jersey, July 16 /PRNewswire/ -- ThalesNano Inc. today announced, that within three years from the original introduction of its H-Cube product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.

The H-Cube(R) Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation reactor, uniquely combining continuous-flow chemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows safe, fast and cost-efficient hydrogenation with superior yield when compared to conventional methods. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shorted development time, increased cost efficiency and reduced environmental impact.

"Having all of the top 20 pharmaceutical companies as H-Cube users is a real testimony that the instrument is changing the process of how drugs are developed and the benefits that can be derived as a result", said Dr. Laszlo Urge, CEO of ThalesNano Inc. "Our early customers are now using our technology at multiple sites on four continents. H-Cube has become their first line of technology for catalytic hydrogenations. After establishing our continuous process technology in the discovery labs of the life sciences industry we are moving into the early scale up and full production with the new versions of the systems."

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "It is clear that our strategy of providing a disruptive technology to the industry is working. The benefits of these technologies over conventional batch chemistry include the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include "Green Chemistry" by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market."

For more information please go to:

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

Contact: Laszlo Urge, Ph.D., CEO, e-mail:, Telephone: +36-1-880-8500

SOURCE ThalesNano Nanotechnology Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
2. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
3. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
6. ViroPharma To Acquire Lev Pharmaceuticals
7. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
8. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
11. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
Post Your Comments:
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list of ... OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 ... Squibb in a European healthcare ... in which the companies will work closely together in ... areas of unmet medical need. The collaboration is underpinned by ... latest LSP fund. This is the first investment by Bristol-Myers ...
(Date:11/23/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing, and ... financial results for the second quarter and first half ... --> --> Second Quarter ... second quarter of fiscal 2016 increased by 12.7% to ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
Breaking Biology News(10 mins):